LEXICON PHARMACEUTICALS INC's ticker is LXRX and the CUSIP is 528872302. A total of 137 filers reported holding LEXICON PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 1.32 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $142,008 | -55.6% | 130,291 | -6.8% | 0.00% | – |
Q2 2023 | $320,025 | +105171.4% | 139,747 | +11.7% | 0.00% | – |
Q1 2023 | $304 | +33.3% | 125,066 | +5.0% | 0.00% | – |
Q4 2022 | $228 | -99.9% | 119,117 | +5.0% | 0.00% | – |
Q3 2022 | $272,000 | +50.3% | 113,395 | +16.3% | 0.00% | – |
Q2 2022 | $181,000 | +8.4% | 97,470 | +21.9% | 0.00% | – |
Q1 2022 | $167,000 | -51.0% | 79,934 | -7.8% | 0.00% | – |
Q4 2021 | $341,000 | -15.6% | 86,660 | +3.2% | 0.00% | -100.0% |
Q3 2021 | $404,000 | +7.7% | 83,991 | +2.7% | 0.00% | – |
Q2 2021 | $375,000 | +16.1% | 81,792 | +48.5% | 0.00% | – |
Q1 2021 | $323,000 | +66.5% | 55,078 | -2.8% | 0.00% | – |
Q4 2020 | $194,000 | +169.4% | 56,689 | +13.0% | 0.00% | – |
Q3 2020 | $72,000 | -44.2% | 50,159 | -22.7% | 0.00% | – |
Q2 2020 | $129,000 | +17.3% | 64,886 | +14.6% | 0.00% | – |
Q1 2020 | $110,000 | -55.8% | 56,607 | -5.8% | 0.00% | – |
Q4 2019 | $249,000 | +40.7% | 60,107 | +2.3% | 0.00% | – |
Q3 2019 | $177,000 | -52.4% | 58,748 | -0.7% | 0.00% | -100.0% |
Q2 2019 | $372,000 | +20.4% | 59,148 | +6.5% | 0.00% | 0.0% |
Q1 2019 | $309,000 | -18.7% | 55,531 | -2.9% | 0.00% | 0.0% |
Q4 2018 | $380,000 | -8.2% | 57,193 | +47.3% | 0.00% | 0.0% |
Q3 2018 | $414,000 | -17.0% | 38,817 | -6.7% | 0.00% | 0.0% |
Q2 2018 | $499,000 | +44.6% | 41,597 | +3.4% | 0.00% | 0.0% |
Q1 2018 | $345,000 | -16.1% | 40,243 | -3.3% | 0.00% | 0.0% |
Q4 2017 | $411,000 | -34.1% | 41,618 | -18.1% | 0.00% | 0.0% |
Q3 2017 | $624,000 | -23.4% | 50,791 | +2.5% | 0.00% | -50.0% |
Q2 2017 | $815,000 | +19.5% | 49,531 | +4.2% | 0.00% | 0.0% |
Q1 2017 | $682,000 | +6.6% | 47,526 | +2.8% | 0.00% | 0.0% |
Q4 2016 | $640,000 | -17.0% | 46,245 | +8.4% | 0.00% | 0.0% |
Q3 2016 | $771,000 | +28.1% | 42,677 | +1.7% | 0.00% | 0.0% |
Q2 2016 | $602,000 | -4.7% | 41,977 | -20.7% | 0.00% | 0.0% |
Q1 2016 | $632,000 | -4.0% | 52,903 | +7.0% | 0.00% | 0.0% |
Q4 2015 | $658,000 | +28.3% | 49,448 | +3.6% | 0.00% | 0.0% |
Q3 2015 | $513,000 | +36.1% | 47,723 | +2.0% | 0.00% | +100.0% |
Q2 2015 | $377,000 | – | 46,807 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ulys, L.L.C. | 4,321,214 | $25,366,000 | 100.00% |
Artal Group S.A. | 71,178,364 | $417,817,000 | 7.38% |
BVF INC/IL | 8,394,000 | $49,273,000 | 1.85% |
Boothe Investment Group, Inc. | 435,939 | $2,559,000 | 1.49% |
Campbell & CO Investment Adviser LLC | 103,100 | $605,000 | 0.37% |
NEA Management Company, LLC | 2,382,286 | $13,984,000 | 0.31% |
PINNACLE ASSOCIATES LTD | 2,167,172 | $12,721,000 | 0.24% |
Eversept Partners, LP | 410,593 | $2,410,181 | 0.18% |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 35,714 | $210,000 | 0.12% |
OCCUDO QUANTITATIVE STRATEGIES LP | 66,299 | $389,000 | 0.08% |